Levobunolol

beta-Adrenergic Blocker — SENSORY ORGANS

Key facts

Levobunolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1985. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 9 molecular targets, including ADRB2, ADRB1 and ADRB3. Recorded indications include Ocular hypertension and Open-angle glaucoma.

• Approval status: ofp (first approved 1985 by the FDA).
• Drug class: beta-Adrenergic Blocker.
• Mechanism of action: Adrenergic beta-Antagonists.
• Molecular targets: ADRB2, ADRB1, ADRB3 and SIGMAR1 (9 listed in DrugCentral).
• Indications: Ocular hypertension and Open-angle glaucoma.
• ATC code: S01ED03 (Beta blocking agents).
• Molecular formula: C17H25NO3; molecular weight 291.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Ocular hypertension
• Open-angle glaucoma

Contraindications (13)

• Acute cerebrovascular insufficiency
• Anaphylaxis
• Asthma
• Cardiogenic shock
• Complete atrioventricular block
• Decompensated cardiac failure
• Diabetes mellitus
• Myasthenia gravis
• Pregnancy, function
• Pulmonary emphysema
• Second degree atrioventricular block
• Severe chronic obstructive pulmonary disease
• Sinus bradycardia

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta-Antagonists
• Established pharmacologic class: beta-Adrenergic Blocker

Molecular targets (9)

Target	Gene	Action	Activity
Beta-2 adrenergic receptor	ADRB2	antagonist	Ki 9.26
Beta-1 adrenergic receptor	ADRB1	antagonist	Ki 8.40
Beta-3 adrenergic receptor	ADRB3	antagonist	Ki 6.59
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.49
Beta-3 adrenergic receptor	Adrb3	antagonist	Ki 6.40
Beta-3 adrenergic receptor	Adrb3	antagonist	Ki 6.30
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 5.78
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 5.58
5-hydroxytryptamine receptor 1A	Htr1a	unknown	IC50 5.54

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-12-19	FDA	—	ALLERGAN

ATC classification

ATC code	Therapeutic hierarchy
S01ED03	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Beta blocking agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Choroidal detachment	49.4
Floppy iris syndrome	45.4
Iridocyclitis	35.8

Chemical structure

• Molecular formula: C₁₇H₂₅NO₃
• Molecular weight: 291.39 g/mol
• CAS number: 47141-42-4
• InChIKey: IXHBTMCLRNMKHZ-LBPRGKRZSA-N
• PubChem CID: 39468

CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Levobunolol used for?

DrugCentral lists the following indications for Levobunolol: Ocular hypertension and Open-angle glaucoma.

How does Levobunolol work?

Levobunolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB2 (antagonist), ADRB1 (antagonist), ADRB3 (antagonist) and SIGMAR1.

When was Levobunolol first approved?

Levobunolol was first approved by the FDA in 1985.

What drug class does Levobunolol belong to?

Levobunolol is in the beta-Adrenergic Blocker class.

What is the chemical formula of Levobunolol?

Levobunolol has the molecular formula C17H25NO3 and a molecular weight of 291.39 g/mol.

Sources

• DrugCentral drug card 431 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201177 — compound record and bioactivity
• PubChem CID 39468 — chemical identifiers
• DrugBank DB01210 — drug record
• FDA UNII G6317AOI7K — substance identity
• DailyMed: FDA labels for Levobunolol — current prescribing information (label search)
• UniProt P07550 (ADRB2) — target protein
• UniProt P08588 (ADRB1) — target protein
• UniProt P13945 (ADRB3) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P08908 (HTR1A) — target protein
• UniProt P31645 (SLC6A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.